Free Trial
NASDAQ:SYRE

Spyre Therapeutics (SYRE) Stock Price, News & Analysis

Spyre Therapeutics logo
$15.24 -0.72 (-4.51%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$15.24 0.00 (0.00%)
As of 08/7/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Spyre Therapeutics Stock (NASDAQ:SYRE)

Key Stats

Today's Range
$14.94
$15.90
50-Day Range
$14.68
$18.56
52-Week Range
$10.91
$40.26
Volume
417,085 shs
Average Volume
557,872 shs
Market Capitalization
$918.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.40
Consensus Rating
Buy

Company Overview

Spyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

SYRE MarketRank™: 

Spyre Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 543rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spyre Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Spyre Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spyre Therapeutics are expected to grow in the coming year, from ($4.46) to ($3.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spyre Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spyre Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spyre Therapeutics has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    26.50% of the float of Spyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spyre Therapeutics has a short interest ratio ("days to cover") of 24.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Spyre Therapeutics has recently increased by 0.82%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Spyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spyre Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.50% of the float of Spyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spyre Therapeutics has a short interest ratio ("days to cover") of 24.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Spyre Therapeutics has recently increased by 0.82%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Spyre Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Spyre Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    2 people have searched for SYRE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spyre Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.43% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Spyre Therapeutics' insider trading history.
Receive SYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SYRE Stock News Headlines

Spyre Therapeutics Announces Grants of Inducement Awards
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More Headlines

SYRE Stock Analysis - Frequently Asked Questions

Spyre Therapeutics' stock was trading at $23.28 at the beginning of the year. Since then, SYRE shares have decreased by 34.5% and is now trading at $15.24.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) issued its earnings results on Tuesday, August, 5th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.24.

Top institutional investors of Spyre Therapeutics include Emerald Advisers LLC (0.94%), Emerald Mutual Fund Advisers Trust (0.55%), TD Asset Management Inc (0.19%) and ProShare Advisors LLC (0.02%).
View institutional ownership trends
.

Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SYRE
Previous Symbol
NASDAQ:SYRE
CIK
1636282
Employees
73
Year Founded
N/A

Price Target and Rating

High Price Target
$65.00
Low Price Target
$27.00
Potential Upside/Downside
+250.4%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$208.02 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-71.30%
Return on Assets
-38.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.49
Quick Ratio
8.06

Sales & Book Value

Annual Sales
$890 thousand
Price / Sales
1,032.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.98 per share
Price / Book
3.06

Miscellaneous

Outstanding Shares
60,280,000
Free Float
50,975,000
Market Cap
$918.67 million
Optionable
Optionable
Beta
2.82
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:SYRE) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners